Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Bioprocess Online and Life Science Connect and brought to you by Cytiva.
Episodes
251 episodes
The Implications Of China's Growing Biotech Industry With Allan Shaw
Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse. Increased deal activity with Chinese biopharmaceutical companies is injecting new...
•
Episode 250
•
46:08
How To Be A CFO With Insmed's Sara Bonstein
On today's episode we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expe...
•
Episode 249
•
44:20
Deal And Investment Trends With Investment Banker David Sans
Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted t...
•
Episode 248
•
46:43
Business of Biotech 2.0 with Ben Comer
After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year jour...
•
34:44
BoB@JPM: Nima Farzan, Latigo Biotherapeutics
In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-o...
•
Episode 246
•
43:32
BoB@JPM: Kasper Roet, Ph.D., QurAlis
Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mechanisms in ALS are now underway. On this episode of the Business of Biotec...
•
Episode 245
•
43:46
BoB@JPM: Rick Modi, Affinia Therapeutics
The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embr...
•
Episode 244
•
52:20
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty
On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an inn...
•
Episode 243
•
56:27
BoB@JPM: Tom Chalberg, Ph.D., Genascence
Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMP...
•
48:00
BoB@JPM: Ran Zheng, Landmark Bio
Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in ...
•
Episode 241
•
37:00
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics
From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. A...
•
Episode 240
•
45:07
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience
From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discus...
•
Episode 239
•
43:00
The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated ...
•
Episode 238
•
47:51
High-Throughput Discovery With Bioptic's Andrey Dobry
Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking YouTube mobile. You heard that right. If it weren't for him and the teams he led, YouTube might still be a desktop experience. He went on to lead product strateg...
•
Episode 237
•
1:13:36
RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D.
In close partnership woth Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of...
•
Episode 236
•
1:06:32
Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal)
Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during the COVID 19 pandemic to learn about his la...
•
Episode 235
•
54:04
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D.
Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers...
•
1:02:34
Biotech Story Time With Tal Zaks, M.D. (Part 1)
Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business...
•
Episode 233
•
55:25
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D.
This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode o...
•
52:50
Manufacturing Partnership With Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski
On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly-appointed CEO at Forge Biologics. We revisit progress at Life Biosc...
•
1:03:50
Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D.
Revolo Biotherapeutics President and CEO Woody Bryan, Ph.D. is pushing the boundaries of peptide therapeutic delivery. On this episode of the Business of Biotech, we dig into Dr. Bryan’s transition to the CEO chair at the company and how that c...
•
45:26
Biopolitics With Allan Shaw
The notion that political influence has no place in biology appears poised for a test it hasn’t studied for. Trump administration nominations, from RFK, Jr. to HHS and Vivek Ramaswamy to the newly-proposed DOGE, are driving a storm of speculati...
•
49:54
T-Cells For The Win With Adaptimmune's Adrian Rawcliffe
In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with unresectable or metastatic synovial sarcoma who have previously received chemotherapy. It marked the first new t...
•
1:01:35
Serving The Underserved With Gates MRI's Claire Wagner, M.D.
On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there. She shares the develop...
•
46:48
An Unanticipated Biotech Startup With OS Therapies' Paul Romness
Becoming a biotech CEO wasn't on Paul Romness' bingo card. He'd forged his place in the biopharma industry as a foremost public and policy affairs expert. Thirteen years at J&J, more than 5 at Amgen, and half a dozen at Boehringer Ingelheim...
•
49:12